Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations

CONCLUSIONS AND CLINICAL IMPLICATIONS: In this hypothesis-generating study, patients with mRCC with synchronous metastasis who were treated with first-line ICI-based combinations have a poorer OS and worse DCR than those with metachronous mRCC. If these results are externally validated, time to metastasis could be included in prognostic models for mRCC.PATIENT SUMMARY: Our study demonstrates that patients treated with current first-line immunotherapies, who present with metastasis at the initial diagnosis of kidney cancer have worse overall survival compared to those who develop metastasis later. These results can help physicians and patients understand life expectancy.PMID:38580524 | DOI:10.1016/j.euf.2024.03.006

Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Georges Gebrael Luis Meza Xiaochen Li Zeynep Zengin Nicolas Sayegh Hedyeh Ebrahimi Nishita Tripathi Daniela Castro Benjamin Mercier Regina Barragan-Carrillo Haoran Li Alexander Chehrazi-Raffle Umang Swami Abhishek Tripathi Neeraj Agarwal Benjamin L Maugha Source Type: research